Suggested remit: To appraise the clinical and cost effectiveness of crovalimab within its marketing authorisation for treating paroxysmal nocturnal haemoglobinuria.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process Cost Comparison Standard
ID number 6140

Provisional Schedule

Expected publication 30 October 2024

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group Kleijnen Systematic Reviews Ltd


Companies sponsors Roche (crovalimab)
Others Department of Health and Social Care
  NHS England
Patient carer groups Aplastic Anaemia Trust
  Genetic Alliance UK
  PNH Support
  Specialised Healthcare Alliance
Professional groups Anaemia Nurse Specialist Association
  British Blood Transfusion Society
  British Geriatrics Society
  British Paediatric Allergy, Immunity and Infection Group
  British Society for Genetic Medicine
  British Society for Haematology
  British Society for Immunology
  National PNH Service
  NHS Blood and Transplant
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  UK Clinical Pharmacy Association
  UK Forum on Haemoglobin Disorders
  United Kingdom National Screening Committee
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Alexion Pharmaceuticals (eculizumab, ravulizumab)
  Amgen (eculizumab)
  Novartis (iptacopan)
  Samsung Bioepis (eculizumab)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Hospital Information Services - Jehovah's Witnesses
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  National Services Division
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Haematological Malignancies Group
  Cochrane UK
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research
  PNH Scotland


Key events during the development of the guidance:

Date Update
09 April 2024 Invitation to participate
13 September 2023 - 11 October 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6140
13 October 2022 In progress. DHSC referral received
15 June 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual